Champions Oncology, Inc. (CSBR) stock analysis
Close on Nov 11, 2026Market cap $66.53MP/E –Yield –
StockData Score
Prices as of Nov 11, 2026How the score works
Mixed9 of 30 checks passed
Champions Oncology passes 9 of the 30 checks behind our score; 12 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.
- Valuation
- 0/6
- Growth
- 1/6
- Past performance
- 3/6
- Financial health
- 5/6
- Dividend
- 0/6
What stands out
No debt
Champions Oncology has no borrowings on its latest balance sheet.
Interest well covered
No meaningful interest expense to cover.
Debt covered by cash flow
There is no debt to cover.
Gross margin improving
Gross margin was 49.8% over the last twelve months, against 48.5% a year earlier.
What to watch
Margin of safety under 20%
The price is 251% above fair value, so there is no margin of safety.
Trading above fair value
The share price of $4.78 is above our fair value estimate of $1.36.
Return on equity under 15%
Return on equity was -29.8% over the last twelve months and averaged -26.2% over five years; we look for 15% on both.
Revenue growing under 10% a year
Revenue grew 3.3% a year over the last three fiscal years, short of the 10% we look for.
Valuation0/6
P/E against its history
Not enough price and earnings history to compare.
P/E against the industry
Needs positive earnings and enough profitable companies in the industry.
EV/EBITDA above its 5-year median
Champions Oncology's EV/EBITDA of 216.3 is above its 5-year median of 43.3.
P/B above the industry
Champions Oncology's price-to-book of 17.09 is above the Drugs median of 2.29.
Trading above fair value
The share price of $4.78 is above our fair value estimate of $1.36.
Margin of safety under 20%
The price is 251% above fair value, so there is no margin of safety.
Growth1/6
Revenue growing under 10% a year
Revenue grew 3.3% a year over the last three fiscal years, short of the 10% we look for.
EPS growth over 3 years
Needs positive EPS three years ago and today.
Earnings acceleration
Needs positive net income now, a year ago and five years ago.
Growing slower than the industry
Revenue grew 6.7% over the last twelve months; the Drugs median is 8.0%.
Company guidance
No outlook found in earnings releases from the last twelve months.
Gross margin improving
Gross margin was 49.8% over the last twelve months, against 48.5% a year earlier.
Past performance3/6
Return on equity under 15%
Return on equity was -29.8% over the last twelve months and averaged -26.2% over five years; we look for 15% on both.
Return on invested capital
Needs operating income and invested capital.
Return on equity above the industry
Champions Oncology's return on equity of -29.8% is above the Drugs median of -58.8%.
Earnings over 5 years
Needs positive net income five years ago and in the latest year.
Net margin above its 5-year average
Net margin was -1.8% over the last twelve months, against a 5-year average of -3.4%.
Net margin above the industry
Champions Oncology's net margin of -1.8% is above the Drugs median of -53.0%.
Financial health5/6
No debt
Champions Oncology has no borrowings on its latest balance sheet.
Debt not rising
With no debt today, leverage cannot have risen.
Debt covered by cash flow
There is no debt to cover.
Interest well covered
No meaningful interest expense to cover.
Short-term assets cover short-term debts
Current assets are 1.03 times current liabilities.
Elevated bankruptcy risk
The Altman Z-score is -0.30; above 3 is the safe zone and below 1.8 the distress zone.
Dividend0/6
No dividend
Champions Oncology has not paid a dividend in the last twelve months.
Yield against Treasuries
No dividend.
Yield against the market
No dividend.
Dividend stability
No dividend.
Earnings cover
No dividend.
Cash-flow cover
No dividend.
Fair value
How we estimate itOur estimate per share
$1.36
The share price is 251% above this estimate.
| Method | Multiple used | Own 5Y median | Industry median | Value per share | Weight |
|---|---|---|---|---|---|
| EV/EBITDA | 30.0× | 43.3× | 17.1× | $0.94 | 78% |
| P/B | 10.2× | 18.0× | 2.3× | $2.85 | 22% |
| Fair value | $1.36 | 100% | |||
Valuation over time
Using the earnings and balance sheet published at each date, not today's.
- P/E at month end
- Own 5-year median 114
- Drugs median 25.1
An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.
Market risk
From the past year of daily prices.
Liquidity
High risk
- Average value traded per day
- $39.28K
- Value traded per 1% price move
- $13.22K
Downside
Medium risk
- Typical loss in a bad month
- 18.9%
- Volatility (annualized)
- 53%
- Sharpe ratio, 1 year
- -0.63
- Beta to the S&P 500 (5Y)
- 0.36
Typical bad-month loss, week by week
Margins
Share of revenue, fiscal years 2012 to 2026
Gross margin
Operating margin
Net margin
Growth rates
Compound annual growth to fiscal 2026
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +4.4% | +3.3% | +7.7% | +18.2% | |
| Gross profit | -0.1% | +5.4% | +7.8% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2021 | FY2026 | Trend |
|---|---|---|---|---|
| Return on equity | -2158.0% | 5.8% | -30.5% | |
| Return on assets | -99.9% | 1.5% | -4.0% | |
| Current ratio | 0.79 | 1.13 | 0.96 | |
| Capex to revenue | 5.0% | 8.0% | 0.9% | |
| Diluted shares | 11M | 15M | 14M |
Where the cash went
Fiscal 2022 to 2026, five years combined
Champions Oncology generated $28.46M from operations and spent $7.75M on capital expenditure, dividends and share buybacks. 91% of that went back into the business.
DuPont analysis
Return on equity split into margin, efficiency and leverage
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2026 | -2.0% | 2.00× | 7.69× | -30.5% |
| FY2025 | 8.3% | 1.95× | 31.29× | 503.0% |
| FY2024 | -14.5% | 1.66× | 22.12× | -532.5% |
| FY2023 | -9.9% | 1.55× | 5.07× | -77.7% |
| FY2022 | 1.1% | 1.56× | 3.81× | 6.6% |
| FY2021 | 0.9% | 1.70× | 3.86× | 5.8% |
| FY2020 | -6.5% | 2.01× | 4.42× | -57.8% |
| FY2019 | 4.4% | 0.30× | 9.04× | 12.0% |
| FY2018 | -7.3% | 2.52× | 39.92× | -732.5% |
| FY2017 | -44.7% | 2.24× | 21.61× | -2158.0% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2026 against fiscal 2025
- ProfitableNet income above zero-$1.18M
- Cash generatingOperating cash flow above zero-$4.47M
- Return on assets improvedROA up on the prior year18.0% → -3.6%
- Earnings backed by cashOperating cash flow above net income-$4.47M vs -$1.18M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose0.94 → 0.96
- No dilutionShare count did not rise14M → 14M
- Gross margin improvedGross margin up on the prior year50.15% → 48.00%
- More efficientAsset turnover rose2.18 → 1.84
See a number that looks wrong?